Bio-Rad Laboratories | BIO - Cash And Equivalent


Bio-Rad Laboratories reported $517M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Agilent USD 1.76B 49M Jun/2026
Becton, Dickinson and Co. USD 708M 105M Jun/2026
Bio Techne USD 264.71M 54.89M Jun/2026
Bio-Rad Laboratories USD 517M 9.8M Jun/2026
Bruker USD 184.9M 51.5M Jun/2026
Charles River Laboratories USD 192.02M 195K Jun/2026
Danaher USD 4.35B 1.35B Jun/2026
General Electric Aerospace USD 9.35B 1.64B Jun/2026
Illumina USD 1.09B 329M Mar/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Laboratory Of America USD 141.8M 839.3M Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Mettler Toledo International USD 51.38M 9.19M Jun/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
OraSure Technologies USD 160.58M 16.38M Jun/2026
Pacific Biosciences Of California USD 61M 4.73M Jun/2026
Quest Diagnostics USD 626M 233M Jun/2026
Repligen USD 606.78M 24.13M Jun/2026
Revvity USD 1.02B 162.62M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Siemens EUR 8.66B 6.6B Mar/2026
Standard Biotools USD 265.77M 147.56M Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Tosoh JPY 179.62B 46.51B Mar/2026
Waters USD 539M 77M Jun/2026